ProQR to Present at the Leerink Partners Global Healthcare Conference

LEIDEN, the Netherlands, Feb. 03, 2016 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA), today announced that Daniel de Boer, Chief Executive Officer, will take part in an analyst led fireside chat during the Leerink Global Healthcare Conference on Wednesday, February 10, 2016 at 2:15pm ET. The conference is being held at the Waldorf Astoria in New York, NY, USA.

The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcast will be available for 30 days following the presentation date.

About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
[email protected]